The rising cost of cancer care has shed light on an important aspect of healthcare delivery. Financial toxicity of therapy must be considered in clinical practice and policy-making. One way to mitigate the impact of financial toxicity of cancer care is by focusing on an approach of healthcare delivery that aims to deliver value to the patient. Should value of therapy be one of the most important determinants of cancer care? If so, how do we measure it? How can we implement it in routine clinical practice? In this viewpoint, we discuss value-based care in systemic therapy in oncology. Strategies to improve the quality of care by incorporating value-based approaches are discussed: use of composite tools to assess the value of drugs, alternati...
New cancer therapies offer the hope of improved diagnosis to patients with life-threatening disease....
Oncological diseases rank high in the structure of population morbidity and mortality. They entail c...
In the era of rapid development of new, expensive cancer therapies, value frameworks have been devel...
Globally, an increasing and aging population is contributing to the prevalence of cancer. To be effe...
Confronted with the different clinical impacts of different treatments, the rising cost of cancer ca...
The goal of value-based healthcare (VBHC) is to focus on improving patient health outcomes within...
In the current health care system, high costs without proportional improvements in quality or outcom...
AbstractThe value of new cancer drugs is maximized when they are used for the right patient in the r...
In the current climate of escalating health care costs, defining value and accurately measuring it a...
Although guidelines recommend some of the most expensive diagnostic methods and therapies, some pati...
Recently, professional and healthcare-related entities have launched frameworks designed to assess t...
Recently, NICE was given the task of governing the Cancer Drug Fund (CDF) in the UK as the latter wa...
BackgroundThe use of systemic therapy near the end of life can expose cancer patients to severe toxi...
Introduction Over the past few years economic stagnation has made the challenge for sustainability ...
Personalized medicine is revolutionizing the delivery of oncological care, promising benefits both a...
New cancer therapies offer the hope of improved diagnosis to patients with life-threatening disease....
Oncological diseases rank high in the structure of population morbidity and mortality. They entail c...
In the era of rapid development of new, expensive cancer therapies, value frameworks have been devel...
Globally, an increasing and aging population is contributing to the prevalence of cancer. To be effe...
Confronted with the different clinical impacts of different treatments, the rising cost of cancer ca...
The goal of value-based healthcare (VBHC) is to focus on improving patient health outcomes within...
In the current health care system, high costs without proportional improvements in quality or outcom...
AbstractThe value of new cancer drugs is maximized when they are used for the right patient in the r...
In the current climate of escalating health care costs, defining value and accurately measuring it a...
Although guidelines recommend some of the most expensive diagnostic methods and therapies, some pati...
Recently, professional and healthcare-related entities have launched frameworks designed to assess t...
Recently, NICE was given the task of governing the Cancer Drug Fund (CDF) in the UK as the latter wa...
BackgroundThe use of systemic therapy near the end of life can expose cancer patients to severe toxi...
Introduction Over the past few years economic stagnation has made the challenge for sustainability ...
Personalized medicine is revolutionizing the delivery of oncological care, promising benefits both a...
New cancer therapies offer the hope of improved diagnosis to patients with life-threatening disease....
Oncological diseases rank high in the structure of population morbidity and mortality. They entail c...
In the era of rapid development of new, expensive cancer therapies, value frameworks have been devel...